REG - Allergy Therapeutics - Results of General Meeting

Allergy TherapeuticsAnnouncement

Yesterday 13:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251229:nRSc0241Na&default-theme=true

RNS Number : 0241N  Allergy Therapeutics PLC  29 December 2025

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

 

Results of General Meeting and Posting of Annual Report 2025

 

29 December 2025 - Allergy Therapeutics plc (AIM: AGY), the fully integrated
commercial biotechnology company specialising in allergy immunotherapies,
announces that at the General Meeting held today, all resolutions were duly
passed.

 

Results of General Meeting

 

All resolutions at the General Meeting were voted on by way of a poll. The
results of the poll were as follows:

 

 Resolution                                                                      For            %      Against    %     Total Votes Cast  Withheld
 Ordinary Resolution
 1.     To authorise the directors to allot shares and to grant rights to        5,813,451,109  99.98  903,088    0.02  5,814,354,197     1,210
 subscribe for or to convert any security into shares in the Company up to an

 aggregate nominal amount of £610,000.00
 Special Resolution
 2.     To disapply pre-emption rights in respect of an allotment of equity      5,810,471,464  99.93  3,882,733  0.07  5,814,354,197     1,210
 securities for cash pursuant to the authority granted by Resolution 1

The General Meeting was held as the Board is considering potentially
undertaking an equity raise which would be structured by issuing New Shares to
new investors and/or existing shareholders in the Company for cash
consideration in one or more private placements on a non-pre-emptive basis
(the "Potential Equity Raise").

In order to facilitate the Potential Equity Raise and to ensure that it could
be swiftly concluded if it progresses, the Board sought and, at the General
Meeting, obtained, shareholder approval for the allotment and issue of up to
610,000,000 ordinary shares of £0.001 each ("New Shares") (which is
approximately 10% of the Company's current issued share capital) on terms that
the Board may determine. In order for the Directors to issue New Shares free
of statutory pre-emption rights, such statutory pre-emption rights must be
dis-applied. Accordingly, the Board sought, and, at the General Meeting,
obtained, shareholder approval to dis-apply pre-emption rights in respect of
the allotment of the New Shares pursuant to the Potential Equity Raise.

At this time, there is no certainty that the Potential Equity Raise will
proceed and at this point no investors have entered into any agreements to
subscribe for New Shares and the amounts and price of any Potential Equity
Raise have not been agreed. To the extent that any money is raised from the
Potential Equity Raise, it would be applied towards the Company's stated
strategy of developing treatments for grass and peanut allergy patients, and
general corporate purposes, including the Company's working capital needs
prior to its anticipated dual listing on the Hong Kong Stock Exchange.

The Directors shall have discretion to determine the terms of the Potential
Equity Raise, including the number of New Shares to be issued (subject to the
limits of the authorities) and the price at which the New Shares will be
issued, as well as the identity of who the New Shares will be issued to.
Further details of the Potential Equity Raise (if it proceeds) will be
announced in due course.

Posting of Annual Report

The Company also announces that it has posted to shareholders the Annual
Report and Accounts for the year ended 30 June 2025. The Annual Report and
Accounts are available to download from the Company's website at
www.allergytherapeutics.com (http://www.allergytherapeutics.com) .

 

For further information, please contact:

 

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

 

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash /Giles Balleny/ Seamus Fricker

Nigel Birks - Life Science Specialist Sales

+44 (0)20 7220 0500

 

ICR Healthcare

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@icrhealthcare.com

 

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapies that have the potential to
cure disease. The Group sells proprietary and third-party products from its
subsidiaries in nine major European countries and via distribution agreements
in an additional ten countries. For more information, please
see www.allergytherapeutics.com (http://www.allergytherapeutics.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMBXBDDUGDDGUC



            Copyright 2019 Regulatory News Service, all rights reserved